Ticker >

Alkem Laboratories share price

Alkem Laboratories Ltd.

NSE: ALKEM BSE: 539523 SECTOR: Pharmaceuticals & Drugs  109k   560   93

5448.00
+7.75 (0.14%)
BSE: 17 May 04:01 PM

Price Summary

Today's High

₹ 5455.55

Today's Low

₹ 5275.1

52 Week High

₹ 5519.1

52 Week Low

₹ 3211.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

65139.01 Cr.

Enterprise Value

64101.03 Cr.

No. of Shares

11.96 Cr.

P/E

38.84

P/B

6.12

Face Value

₹ 2

Div. Yield

0.92 %

Book Value (TTM)

₹  890.67

CASH

2163.87 Cr.

DEBT

1125.89 Cr.

Promoter Holding

56.74 %

EPS (TTM)

₹  140.26

Sales Growth

2.55%

ROE

12.54 %

ROCE

13.17%

Profit Growth

-26.39 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alkem Laboratories Ltd.

CLAVAM TAXIM Livoerb Pregakem PLAYGARD CONDOMS

Index Presence

The company is present in 29 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.55%
3 Year10.69%
5 Year11.39%

Profit Growth

1 Year-26.39%
3 Year-3.55%
5 Year9.65%

ROE%

1 Year12.54%
3 Year18.54%
5 Year18.52%

ROCE %

1 Year13.17%
3 Year18.19%
5 Year18.42%

Debt/Equity

0.1204

Price to Cash Flow

45.32

Interest Cover Ratio

16.3586805555556

CFO/PAT (5 Yr. Avg.)

0.854172568038275

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 56.74 0
Dec 2023 56.74 0
Sep 2023 56.74 0
Jun 2023 57.16 0
Mar 2023 57.16 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 1119.63 Cr.
  • Company has a healthy Interest coverage ratio of 16.3586805555556.
  • The company has an efficient Cash Conversion Cycle of 20.2171655665838 days.
  • Company has a healthy liquidity position with current ratio of 2.22416686645888.
  • The company has a high promoter holding of 56.74%.

 Limitations

  • The company has shown a poor profit growth of -3.55037286158381% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.6860755730632% for the Past 3 years.
  • Tax rate is low at 14.5080219142571.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 2296.72 2237.99 2253.17 2634.59 2494.59
Total Expenditure 1840.75 1906 1919.42 1979.99 1925.33
Operating Profit 455.97 331.99 333.75 654.6 569.26
Other Income 60.74 76.6 64.7 61.84 95.66
Interest 22.62 21.74 21.42 18.7 21.11
Depreciation 58.14 57.16 58.11 59.02 58.12
Exceptional Items 0 0 0 0 -51.31
Profit Before Tax 435.95 329.69 318.92 638.72 534.38
Tax 47.06 74.9 47.48 -7.79 30.15
Profit After Tax 388.89 254.79 271.44 646.51 504.23
Adjusted EPS (Rs) 32.53 21.31 22.71 54.08 42.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 5714.09 6677.08 7219.68 8829.81 9054.55
Total Expenditure 4668.38 5209.43 5270.75 7019.45 7677.6
Operating Profit 1045.71 1467.65 1948.93 1810.36 1376.95
Other Income 67.58 95.98 190.01 199.89 266.29
Interest 28.26 38.71 42.93 37.9 86.4
Depreciation 141.07 186.84 198.93 218.98 229.85
Exceptional Items 0 0 -12.78 0 0
Profit Before Tax 943.96 1338.08 1884.3 1753.37 1326.99
Tax 144.12 73.66 199.22 212.12 192.52
Net Profit 799.84 1264.42 1685.08 1541.25 1134.47
Adjusted EPS (Rs.) 66.9 105.77 140.95 128.92 94.9

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 23.91 23.91 23.91 23.91 23.91
Total Reserves 5441.3 6256.53 7601.84 8719.75 9325.94
Borrowings 6.32 6.32 0 0 0
Other N/C liabilities -485.84 -579.85 -717.39 -746.99 -748.38
Current liabilities 1669.87 2579.76 2909.94 4123.76 3044.83
Total Liabilities 6655.56 8286.67 9818.3 12120.43 11646.3
Assets
Net Block 1606.38 1836.76 1758.36 1882.07 1825.09
Capital WIP 381.59 313.66 323.26 232.45 185.1
Intangible WIP 0 0 0 0 43.65
Investments 1476.42 1794.52 1990.21 2393.45 2692.96
Loans & Advances 87.03 100.11 102.02 133.05 112.92
Other N/C Assets 41.43 28.19 18.46 620.53 14.37
Current Assets 3062.71 4213.43 5625.99 6858.88 6772.21
Total Assets 6655.56 8286.67 9818.3 12120.43 11646.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 943.96 1338.08 1884.3 1753.37 1326.99
Adjustment 130.06 141.24 123.34 107.99 128.89
Changes in Assets & Liabilities -124.43 -563.6 -361.86 -227.17 205.7
Tax Paid -204.5 -233.94 -321.3 -334.85 -224.16
Operating Cash Flow 745.09 681.78 1324.48 1299.34 1437.42
Investing Cash Flow -313.06 -995.17 -1120.99 -1669.33 197.04
Financing Cash Flow -275.75 172.64 -208.96 436.59 -1711.27
Net Cash Flow 156.28 -140.75 -5.47 66.6 -76.81

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 57.16 57.16 56.74 56.74 56.74
aniruddha singh& (please ... - - 1.01 1.01 1.01
archana singh - - 2.00 2.00 2.00
basudeo narain singh 7.27 7.27 7.27 7.27 7.27
divya singh& (please refe... - - - - 1.01
inderjit kaur arora# (ple... 0.01 0.01 0.01 0.01 0.01
jayanti sinha 4.30 4.30 4.30 2.46 2.46
madhurima singh$ (please ... - - - - 5.39
madhurima singh& (please ... - - 0.79 0.79 0.79
madhurima singh@ (please ... 0.02 0.02 0.02 0.02 2.59
manju singh# (please refe... - - 0.08 0.08 0.08
meghna singh - - 1.01 1.01 1.01
mritunjay kumar singh 6.42 6.42 6.42 6.42 6.42
raj kumar singh 0.45 0.45 0.45 0.45 0.45
sadhika raj - - - - 0.46
sakshi sinha - - - - 0.46
sarandhar singh# (please ... 0.07 0.07 0.07 0.07 0.07
sarandhar singh* (please ... 21.08 21.08 20.66 20.66 20.66
sarvesh singh# (please re... - - 0.07 0.07 0.07
satish kumar singh# (plea... 0.06 0.06 0.06 0.06 0.06
satyam sinha - - - - 0.46
seema singh - - 2.46 2.46 2.46
shikhar raj - - - - 0.46
shrey shree anant singh 1.00 1.00 1.00 1.00 1.00
srinivas singh# (please r... 0.09 0.09 0.09 0.09 0.09
dhananjay kumar singh 7.96 7.96 7.96 7.96 -
divya singh - - 1.01 1.01 -
sadhika raj$ (please refe... - - - 0.46 -
sakshi sinha$ (please ref... - - - 0.46 -
satyam sinha$ (please ref... - - - 0.46 -
shikhar raj$ (please refe... - - - 0.46 -
aniruddha singh & (please... 1.01 1.01 - - -
archana singh 2.00 2.00 - - -
divya singh 1.01 1.01 - - -
madhurima singh & (pleas... 0.79 0.79 - - -
manju singh# (please ref... - 0.08 - - -
meghna singh 1.01 1.01 - - -
sarvesh singh# (please r... 0.07 0.07 - - -
seema singh 2.46 2.46 - - -
balmiki prasad singh 0.08 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 42.84 42.84 43.26 43.26 43.26
alok kumar - - 2.31 2.31 2.31
ashok kumar 2.31 2.31 2.31 2.26 2.26
deepak kumar singh 2.28 2.26 2.20 2.17 2.16
dsp midcap fund 2.95 3.18 3.37 2.90 2.53
government pension fund g... - - 1.05 - 1.06
hdfc life insurance compa... 1.17 1.22 1.44 1.44 1.40
icici prudential elss tax... - - - 2.25 2.24
kishor kumar singh - - 2.86 2.86 2.86
llp 0.01 0.01 0.01 0.01 0.01
nawal kishore singh 2.08 1.88 1.47 1.09 1.01
nippon life india trustee... 1.15 1.31 1.43 1.26 1.56
rajeev ranjan 2.37 2.37 2.08 2.08 2.08
rajesh kumar 2.54 2.54 2.25 2.25 2.25
bnp paribas financial mar... - - - 1.06 -
sbi contra fund - - 1.24 1.13 -
icici prudential value di... - - 2.75 - -
alok kumar 2.31 2.31 - - -
icici prudential long ter... - 2.34 - - -
kishor kumar singh 2.86 2.86 - - -
life insurance corporatio... 3.94 1.70 - - -
icici prudential pharma h... 1.80 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Alkem Laboratories incorporates wholly owned subsidiary28 Mar 2024, 3:55PM USFDA concludes inspection at Alkem Laboratories’ manufacturing facility at Baddi28 Mar 2024, 11:42AM Alkem Laboratories informs about notice of postal ballot6 Mar 2024, 3:39PM Alkem Laboratories informs about press release 28 Feb 2024, 5:00PM USFDA issues EIR for Alkem Laboratories’ API manufacturing facility at Mandva 28 Feb 2024, 3:47PM Alkem Laboratories informs about clarification27 Feb 2024, 3:06PM Alkem Laboratories informs about clarification media statement26 Feb 2024, 2:41PM Alkem Laboratories informs about disclosure 16 Feb 2024, 5:00PM Alkem Laboratories informs about transcript of conference call14 Feb 2024, 2:15PM Alkem Laboratories - Quaterly Results9 Feb 2024, 1:17PM Alkem Laboratories - Quaterly Results9 Feb 2024, 1:17PM Alkem Laboratories - Quaterly Results9 Feb 2024, 1:17PM Alkem Laboratories completes sale of unit in US for consideration of $7.96 million1 Jan 2024, 10:41AM Alkem Laboratories informs about sale of St. Louis manufacturing facility 30 Dec 2023, 3:06PM Alkem Laboratories informs about closure of trading window 21 Dec 2023, 12:19PM Alkem Laboratories informs about analyst meet13 Dec 2023, 3:36PM Alkem Laboratories informs about press release 8 Dec 2023, 1:54PM Alkem Laboratories informs about notice of postal ballot7 Dec 2023, 3:57PM USFDA concludes inspection at Alkem Laboratories’ API manufacturing facility in Maharashtra2 Dec 2023, 3:42PM Alkem Laboratories informs about analyst meet29 Nov 2023, 5:27PM Alkem Laboratories informs about analyst meet 23 Nov 2023, 3:25PM Alkem Laboratories informs about audio recording of conference call8 Nov 2023, 2:31PM Alkem Laboratories informs about outcome of board meeting7 Nov 2023, 4:33PM Alkem Laboratories informs about cut-off date for postal ballot7 Nov 2023, 2:47PM Alkem Laboratories - Quaterly Results7 Nov 2023, 1:50PM Alkem Laboratories - Quaterly Results7 Nov 2023, 1:50PM Alkem Laboratories - Quaterly Results7 Nov 2023, 1:50PM Alkem Laboratories informs about analyst meet 25 Sep 2023, 5:03PM Alkem Laboratories informs about press release25 Sep 2023, 11:58AM Alkem Laboratories, Biosergen collaborate to develop anti-infective for fungal infections25 Sep 2023, 10:58AM Alkem Laboratories submits analyst meet intimation31 Aug 2023, 3:32PM Alkem Laboratories informs about investor meeting 25 Aug 2023, 12:21PM Alkem Laboratories reports over 2-fold jump in Q1 consolidated net profit10 Aug 2023, 3:51PM Alkem Laboratories informs about press release and analyst presentation10 Aug 2023, 2:35PM Alkem Laboratories - Quaterly Results10 Aug 2023, 1:56PM Alkem Laboratories - Quaterly Results10 Aug 2023, 1:56PM Alkem Laboratories - Quaterly Results10 Aug 2023, 1:56PM Alkem Laboratories informs about newspaper advertisement 15 Jul 2023, 12:54PM Alkem Laboratories informs about compliance certificate13 Jul 2023, 4:42PM Alkem Laboratories enters into ophthalmology segment7 Jul 2023, 11:18AM Alkem Laboratories informs about investor meeting 26 Jun 2023, 3:20PM Alkem Laboratories reports 37% fall in Q4 consolidated net profit 19 May 2023, 3:00PM Alkem Laboratories - Quaterly Results19 May 2023, 1:46PM Alkem Laboratories - Quaterly Results19 May 2023, 1:46PM Alkem Laboratories - Quaterly Results19 May 2023, 1:46PM USFDA conducts inspection at Alkem Laboratories’ API manufacturing facility in Gujarat8 Apr 2023, 12:31PM Alkem Laboratories submits press release 8 Apr 2023, 12:17PM Alkem Laboratories informs about compliance certificate6 Apr 2023, 12:41PM Alkem Laboratories informs about closure of trading window27 Mar 2023, 2:45PM Alkem Laboratories informs about institutional investor meeting20 Mar 2023, 12:33PM

Alkem Laboratories Stock Price Analysis and Quick Research Report. Is Alkem Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alkem Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alkem Laboratories cash from the operating activity was Rs 1437.42 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alkem Laboratories has a Debt to Equity ratio of 0.1204 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alkem Laboratories , the EPS growth was -26.3929072843059 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alkem Laboratories has OPM of 15.2072714822934 % which is a good sign for profitability.
     
  • ROE: Alkem Laboratories have a average ROE of 12.5400765246765 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alkem Laboratories is Rs 5437.7. One can use valuation calculators of ticker to know if Alkem Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Alkem Laboratories

Alkem Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to the Alkem Laboratories Ltd. Stock Analysis page! If you're a long-term stock investor seeking comprehensive stock analysis and insights, you're in the right place. We have a range of tools and resources to help you evaluate the potential of Alkem Laboratories Ltd., a renowned pharmaceutical company in India.

Alkem Laboratories Ltd. Share Price:

The share price of Alkem Laboratories Ltd. is a crucial factor for long-term stock investors. It serves as an indicator of market sentiment and investor perception towards the company. Monitoring the share price trend is essential to identify potential buying opportunities or risks associated with the stock. At our Stock Analysis page, we offer pre-built screening tools that enable investors to track the share price of Alkem Laboratories Ltd. and make well-informed investment decisions.

Alkem Laboratories Ltd. Balance Sheet:

For long-term stock investors, analyzing the balance sheet of Alkem Laboratories Ltd. is crucial to assess the financial health of the company. Our Stock Analysis page provides pre-built screening tools that allow investors to evaluate the company's asset base, liabilities, and overall financial stability. By analyzing the balance sheet, you can gauge the company's ability to manage debt and make informed investment decisions. We also provide premium feature tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis to help you evaluate the stock.

Alkem Laboratories Ltd. Annual Report:

The annual report of Alkem Laboratories Ltd. is a goldmine of information for long-term stock investors. It provides detailed insights into the company's performance, future prospects, and management strategies. At our Stock Analysis page, you can access and download the annual reports of Alkem Laboratories Ltd. These reports consist of the CEO's letter, financial statements, and discussions on key management initiatives. By reviewing the annual reports, you can perform a thorough analysis of the company, assess its operations, growth prospects, and make informed investment decisions.

Alkem Laboratories Ltd. Dividend:

Dividend payouts are an attractive feature for long-term stock investors. They indicate the financial stability and growth prospects of a company. At our Stock Analysis page, you can evaluate the dividend policies of Alkem Laboratories Ltd. using our pre-built screening tools. These tools help you assess the company's dividend payouts and their long-term sustainability. Tracking the dividend payouts enables you to gauge the company's profitability, financial stability, and make informed investment decisions.

Alkem Laboratories Ltd. Quarterly Result:

Keeping up with the latest financial performance of Alkem Laboratories Ltd. is essential for long-term stock investors. Our Stock Analysis page provides screening tools that enable investors to analyze the company's quarterly results. By identifying significant trends and patterns in the quarterly results, you can gain insights into the short-term growth and performance of the company. These insights aid in assessing the company's financial health, growth prospects, and making informed investment decisions.

Alkem Laboratories Ltd. Stock Price:

The stock price of Alkem Laboratories Ltd. on the market dictates investor interest. Understanding the stock price trend is key to gauging the market's perception of the company's growth potential. At our Stock Analysis page, we provide screening tools to help you track the stock price of Alkem Laboratories Ltd. and analyze the market trend. By leveraging these tools, you can evaluate the market potential, identify buying opportunities, and assess the company's growth prospects.

Alkem Laboratories Ltd. Price Chart:

Analyzing the price chart of Alkem Laboratories Ltd. offers valuable insights into the historical stock price movements. Our Stock Analysis page provides screening tools for analyzing the price chart. By identifying trends and patterns, you can potentially anticipate investor behavior. Studying the price chart aids in gaining insights into the company's growth potential and market sentiment towards the stock.

Alkem Laboratories Ltd. News:

Staying informed with the latest news about Alkem Laboratories Ltd. is crucial for long-term stock investors. Our Stock Analysis page offers a comprehensive collection of news articles from various sources. These articles include financial news websites and social media platforms. By staying up-to-date, you gain valuable insights into the company's operations, strategic initiatives, and potential market trends. These insights help you make well-informed investment decisions.

Alkem Laboratories Ltd. Concall:

Alkem Laboratories Ltd. conducts conference calls, known as concalls, with analysts and investors. Our Stock Analysis page provides information about upcoming concalls and access to insights from previous calls. Listening to these concalls offers a deeper understanding of the company's operations, financial performance, and future plans. Utilizing the information gained from these calls enables you to assess the company's financial health, growth prospects, and make informed investment decisions.

Alkem Laboratories Ltd. Transcripts:

Accessing the transcripts of Alkem Laboratories Ltd.'s concalls and management meetings is invaluable for long-term stock investors. At our Stock Analysis page, you can download these transcripts. Transcripts offer detailed records of the discussions held during these calls, providing insights into the company's operations, financial performance, and market outlook. Reviewing these transcripts helps you perform a comprehensive analysis of the company's financial health, growth prospects, and management strategies.

Alkem Laboratories Ltd. Investor Presentations:

Alkem Laboratories Ltd. provides investor presentations on its website, offering detailed information about its financial performance, strategic initiatives, and future plans. Our Stock Analysis page provides easy access to these presentations. Examining these presentations is essential for evaluating the company's long-term viability and investment potential. These presentations, along with our premium feature tools, assist you in analyzing the stock and making informed investment decisions.

Alkem Laboratories Ltd. Promoters:

Analyzing the holdings of a company's promoters is crucial for long-term stock investors. At our Stock Analysis page, you can use our pre-built screening tools to evaluate the promoter holdings of Alkem Laboratories Ltd. This analysis offers insights into potential conflicts of interest and the company's ownership structure. Understanding the significance of promoter holdings helps you assess the company's strength, growth prospects, and long-term viability.

Alkem Laboratories Ltd. Shareholders:

The composition of Alkem Laboratories Ltd.'s shareholder base is an essential consideration for long-term investors. Our Stock Analysis page provides pre-built screening tools to analyze the shareholder base. This analysis offers insights into potential risks and opportunities associated with the stock. Understanding the shareholder base helps you assess the company's stability, growth prospects, and long-term potential.

Alkem Laboratories Limited ROCE

The Return on Capital Employed (ROCE) is an important financial metric that evaluates a company's profitability and efficiency in utilizing its capital investments. Alkem Laboratories Limited ROCE analysis provides investors with insights into the company's ability to generate profits from its invested capital. By comparing the operating profit with the total capital employed, the ROCE ratio offers a clear understanding of Alkem Laboratories Limited's financial performance. Investors can easily access the ROCE data for the company on this page in the financials table or ratio section.

Alkem Laboratories Limited EBITDA

EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a crucial financial indicator in evaluating a company's operating performance and cash flow generation. The Alkem Laboratories Limited EBITDA analysis provides investors with an understanding of the company's profitability before accounting for non-operating expenses and the impact of financing decisions. By assessing EBITDA, investors can make informed decisions about Alkem Laboratories Limited's operational efficiency. The EBITDA data for the company can be found on this page in the financials table or ratio section.

Alkem Laboratories Limited DPS

Dividends Per Share (DPS) is a metric that showcases the amount of income distributed to shareholders as dividends for each share they own. Alkem Laboratories Limited DPS analysis allows investors to assess the company's dividend payment history and the dividend yield it offers to shareholders. By examining the DPS data, investors can gain insights into Alkem Laboratories Limited's commitment to returning profits to its shareholders. Investors can find the DPS information for the company on this page in the financials table or ratio section.

Alkem Laboratories Limited EPS

Earnings Per Share (EPS) is a significant financial metric that provides insights into a company's profitability on a per-share basis. Alkem Laboratories Limited EPS analysis enables investors to evaluate the company's earnings performance and compare it with other companies in the industry. By examining the EPS data, investors can gauge Alkem Laboratories Limited's ability to generate profits for its shareholders. The EPS information for the company is available on this page in the financials table or ratio section.

Read More
X